MARKET WIRECNBC • 1h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why CPHI Stock surged +4.84% Today — RQD Quant Desk Flash
$0.65 +4.84% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
China Pharma Holdings Inc. (CPHI) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $28.0M
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-6.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CPHI)Realized 20D OHLCV Swing Band: ±12.5%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CPHI Stock surged +4.84% Today — RQD Quant Desk Flash
China Pharma Holdings Inc. (CPHI) surged +4.84% to $0.65, trading at 2% of its 52-week range ($0.38 – $19.19). Stretched risk/reward at current multiples (-11% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.38 – $19.19) with RSI-14 at 40.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.65 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 0% gross margin and $88937 annual free cash flow.
Live CPHI Headlines & Catalysts
MARKET WIRECNBC • 2h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 3h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 4h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 5h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 6h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 6h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 6h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CPHI)
- ✓Walkthrough of CPHI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CPHI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.37%⚡ TESTING RESISTANCE
2026-10-30O $0.65H $0.67L $0.61C $0.65VOL 182.5K
RES: $1.25SUP: $0.60SMA50: $0.76SMA200: $0.83
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CPHI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -8.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CPHI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CPHI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CPHI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CPHI)
Health Care Rank #489 of 1016
⚔️ ABVC vs CPHI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CPHI vs. ABVC, CELU, BCTX, RNAZ)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, China Pharma Holdings Inc. (CPHI) ranks #489 by composite RQD confidence (45/100, grade D) and #810 by equity capitalization ($28.0M). Within this direct 5-issuer industry benchmark cohort, CPHI leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. RNAZ currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with CPHI at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CPHI
ACTIVE
China Pharma Holdings Inc. | D | 45/100 | — | -3.2% | -11.4% | +4.84% | $28.0M | Benchmark Subject |
| ABVC ABVC BioPharma Inc. | E | 34/100 | — | — | -35.0% | -4.59% | $27.8M | /abvc-vs-cphi → |
| CELU Celularity Inc. (Class A) | E | 34/100 | — | 24.4% | -35.0% | -9.66% | $27.6M | /celu-vs-cphi → |
| BCTX BriaCell Therapeutics Corp. | D- | 41/100 | — | — | — | -5.43% | $28.9M | /bctx-vs-cphi → |
| RNAZ TransCode Therapeutics Inc. | D | 47/100 | — | — | -35.0% | -0.57% | $29.3M | /rnaz-vs-cphi → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001106644In its most recent audited fiscal period (FY2025, filed 2025-12-31), China Pharma Holdings Inc. (CPHI) reported GAAP revenue of $4.1M (-8.5% vs. FY2024 revenue of $4.5M , and -40.9% cumulative change since FY2023) , GAAP net income of -$3.2M, operating cash flow of $148.3K, and free cash flow of $88.9K (+120.0% YoY). On the balance sheet, CPHI closed FY2025 with $31.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $4.1M | -$3.2M | $148.3K | $88.9K | $31.0M | — |
| FY2024 (FY) | 2024-12-31 | $4.5M | -$4.7M | -$406.1K | -$444.5K | $14.9M | — |
| FY2023 (FY) | 2023-12-31 | $7.0M | -$3.1M | -$699.7K | -$699.7K | — | — |
3. CPHI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CPHI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, China Pharma Holdings Inc. (NYSE: CPHI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.65 (+4.84% 1D, market cap $28.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CPHI ranks #489 in composite RQD confidence.
How does CPHI compare to ABVC and CELU in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPHI carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of -3.2%, and ROIC of -11.4%. By comparison, ABVC (ABVC BioPharma Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $27.8M) and CELU (Celularity Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $27.6M). Among the 5-stock peer group, CPHI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CPHI?
Per CPHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001106644), China Pharma Holdings Inc. generated $4.1M in revenue (-8.5% YoY), -$3.2M in net income, and $88.9K in free cash flow against $31.0M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CPHI trading relative to its 50-day, 200-day, and 52-week technical levels?
CPHI last traded at $0.65 (+4.84% on volume of 154,589 shares), positioning the stock -14.47% below its 50-day simple moving average ($0.76) and -21.69% below its 200-day simple moving average ($0.83). Across its 52-week range of $0.38 to $19.19, CPHI sits at the 1.4% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.73).
CPHI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CPHI stock moving today?
Why CPHI Stock surged +4.84% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-11% return on capital) under elevated 10-year interest-rate pressure.